Top 15 Companies in Global Single Nucleotide Polymorphism (SNP) Market (2025–2035): Spherical Insights Analysis

Description

According to a research report published by Spherical Insights & Consulting, The Global Single Nucleotide Polymorphism (Snp) Market Size Is Projected To Grow From USD 8.7 Billion In 2025 To USD 20.8 Billion By 2035, At A CAGR Of 9.11% During The Forecast Period 2025–2035. The global single nucleotide polymorphism (snp) market expansion results from three factors which include the increasing need for personalized medicine and the progress of genomic technologies and their rising application in disease diagnosis and drug development. The market experiences worldwide expansion because of two factors which include research investments and declining sequencing costs and the growing use of healthcare and biotechnology applications.

 

Introduction

The global single nucleotide polymorphism (snp) market refers to the segment of the biotechnology and genomics industry that focuses on identifying and analyzing genetic variations at a single nucleotide level in DNA sequences. Researchers use SNP technologies to conduct research and perform clinical diagnostics and develop drugs and create personalized medical treatments which help them understand genetic differences between people. Through their genetic analysis abilities SNP tests show how different people will react to treatments and disease risks and genetic disorders which leads to better healthcare results. The market is expanding rapidly because of three factors which include rising demand for precision medicine and increasing genetic research with supportive government initiatives in genomics. The decreasing DNA sequencing costs together with the progress in genotyping technologies now offer better accuracy and easier access to scientists. The increasing use of these technologies in cancer research and pharmacogenomics and agricultural biotechnology research drives their faster market acceptance. SNP analysis enables researchers to create targeted therapies which they use to develop customized treatment strategies. The genomics market shows identical patterns which healthcare organizations use to analyze data because genetic testing has become crucial for contemporary medical practices throughout the world.

 

 

Navigate Future Markets with Confidence: Insights from Spherical Insights LLP

The insights presented in this blog are derived from comprehensive market research conducted by Spherical Insights LLP, a trusted advisory partner to leading global enterprises. Backed by in-depth data analysis, expert forecasting, and industry-specific intelligence, our reports empower decision-makers to identify strategic growth opportunities in fast-evolving sectors. Clients seeking detailed market segmentation, competitive landscapes, regional outlooks, and future investment trends will find immense value in the full report. By leveraging our research, businesses can make informed decisions, gain a competitive edge, and stay ahead in the transition toward sustainable and profitable solutions.

 

Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Single Nucleotide Polymorphism (SNP) Market.

 

Market Segmentation

Global Single Nucleotide Polymorphism (SNP) Market Size, Share, By Sample Type (Genomic DNA, RNA, Cell-free DNA (cfDNA), Plasma Samples and Whole Blood), By Technology (Sanger Sequencing, Next-Generation Sequencing (NGS), Microarray-Based Genotyping, PCR-Based Genotyping and Whole Genome Sequencing (WGS)), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035

 

Single Nucleotide Polymorphism (SNP) Market Size & Statistics

• The Market Size for Single Nucleotide Polymorphism (SNP) Was Estimated to be worth USD 8.7 Billion in 2025.
• The Market is Going to Expand at a CAGR of 9.11% between 2025 and 2035.
• The Global Single Nucleotide Polymorphism (SNP) Market Size is anticipated to reach USD 20.8 Billion by 2035.
• North America is expected to generate the highest revenue during the forecast period in the Single Nucleotide Polymorphism (SNP) Market
• Asia Pacific is expected to grow at the fastest rate during the forecast period in the Single Nucleotide Polymorphism (SNP) Market.

Regional growth and demand                                  

Asia Pacific is expected to grow at the fastest rate during the forecast period in the single nucleotide polymorphism (snp) market. The Asia Pacific region is projected to witness the fastest growth in snp single nucleotide polymorphism market during the forecast period with a compound annual growth rate of 11.0%. This growth is driven by increasing investments in genomics research, expanding healthcare infrastructure, rising awareness of personalized medicine, and growing biotechnology industries in countries such as China, India, and Japan.

 

North America is expected to generate the highest revenue during the forecast period in the single nucleotide polymorphism (snp) market. North America holds the largest SNP Single Nucleotide Polymorphism Market share, accounting for 42% of the global market in 2024. The region's dominant position results from its advanced healthcare infrastructure and widespread use of genomic technologies and its high number of biotechnology firms and growing funding for precision medicine and genetic research.

 

 

Top 10 Trends in the Single Nucleotide Polymorphism (SNP) Market

• Rising demand for personalized and precision medicine
• Increasing use of SNP analysis in disease diagnosis
• Growth in cancer genomics and genetic research
• Advancements in genotyping and sequencing technologies
• Declining cost of DNA sequencing
• Expanding applications in pharmacogenomics
• Integration of AI and bioinformatics tools
• Increasing government and private research funding
• Growing adoption in agricultural biotechnology
• Rising demand for large-scale genomic data analysis

 

• Rising Demand for Personalized and Precision Medicine

The Single Nucleotide Polymorphism market experiences its main growth because people want personalized medical treatments and precision-based treatment methods. SNP analysis helps scientists discover genetic differences which determine how people react to medical conditions and their treatments. Healthcare providers use this knowledge to develop targeted therapies which match specific patient needs, resulting in better treatment results and fewer negative consequences. Healthcare systems start using SNP-based solutions because people become more aware about precision medicine. Pharmaceutical companies depend on SNP data to create better drugs which establishes this pattern as a fundamental factor that drives both market expansion and innovative developments.

 

• Increasing Use of SNP Analysis in Disease Diagnosis

People increasingly use SNP analysis for disease diagnosis, especially when diagnosing genetic disorders and complex diseases like diabetes and cardiovascular conditions. Healthcare professionals use genetic variation identification to pinpoint disease risks during their initial development stages. The system enables users to implement preventive care solutions which result in better health outcomes for patients. Clinical laboratories and research institutions are expanding their use of SNPs for diagnostic purposes. Diagnostic facilities are starting to use SNP-based testing because its accuracy has improved through advances in diagnostic technology, which has made testing more readily available to healthcare facilities worldwide.

 

• Growth in Cancer Genomics and Genetic Research

Cancer genomics has developed into a fast-growing research area which depends on SNP analysis for studying genetic mutations that lead to cancer. Researchers utilize SNP data to investigate cancer risk elements and examine tumor characteristics while creating specific treatment methods. The current trend in genetic research together with clinical trials receives substantial funding. The use of SNP analysis enables both early cancer detection and development of individualized treatment plans which results in better patient survival rates. The increasing number of global cancer cases drives the need for sophisticated genomic technologies which results in cancer genomics becoming a key factor in the expansion of the SNP market.

 

• Advancements in Genotyping and Sequencing Technologies

Genotyping and sequencing technologies have developed through recent technical improvements which enable them to perform SNP analysis with higher capacity than before. Current technologies enable genetic variation detection through methods which provide faster results and improved accuracy while maintaining lower costs. Researchers can use high-throughput sequencing together with automated platforms to process enormous amounts of genetic material in a speedy and effective manner. The latest advancements bring better reliability to SNP research methods while enabling their use in both medical and scientific settings. The ongoing development of technology will lead to decreased expenses together with improved availability which will drive more industries to adopt SNP analysis methods.

 

• Declining Cost of DNA Sequencing

The decreasing price of DNA sequencing creates a major driving force which leads to the expansion of the SNP market. The implementation of new sequencing technologies together with the rise of multiple competing service providers has resulted in major price decreases for genetic testing services. These developments make SNP analysis available to researchers and healthcare professionals and general public users. The decreased costs of genomic research allow researchers to conduct extensive genomic studies while enabling clinical and research environments to use SNP testing methods. The global SNP market experiences rapid expansion because organizations and individuals increasingly adopt SNP-based solutions which become more affordable.

 

Empower your strategic planning:

Stay informed with the latest industry insights and market trends to identify new opportunities and drive growth in the single nucleotide polymorphism (snp) market. To explore more in-depth trends, insights, and forecasts, please refer to our detailed report.

 

Top 15 Companies Leading the Single Nucleotide Polymorphism (SNP) Market

1. Thermo Fisher Scientific
2. Illumina, Inc.
3. QIAGEN N.V.
4. F. Hoffmann-La Roche Ltd
5. Agilent Technologies
6. Bio-Rad Laboratories
7. LGC Group
8. Standard BioTools Inc.
9. Revvity, Inc.
10. Takara Bio Inc.
11. Danaher Corporation
12. Eurofins Scientific
13. BGI Genomics Co., Ltd.
14. Oxford Nanopore Technologies
15. Merck KGaA

 

• Thermo Fisher Scientific

Headquarters: Waltham, Massachusetts, USA

Thermo Fisher Scientific operates as the leading company worldwide within the Single Nucleotide Polymorphism (SNP) market by delivering genomic analysis solutions and advanced tools for research and clinical purposes. The company provides support through its SNP genotyping and molecular diagnostics services and sequencing technologies to different sectors, which include healthcare and biotechnology and pharmaceutical companies. The company enables precise identification of genetic variations through its reliable high-performance systems and groundbreaking technology solutions. The company offers its solutions to scientists, who use them in their research on diseases and drug development and precision medicine. The company maintains a worldwide presence while dedicating resources to scientific research, which enables them to develop genomic science and personalized healthcare solutions across the globe.

 

• Illumina, Inc.

Headquarters: San Diego, California, USA

Illumina, Inc. operates as a leading company in the SNP market because it provides advanced technologies, which include sequencing and genotyping methods. The company provides high-throughput platforms that enable large-scale SNP analysis for research and clinical applications. Illumina’s solutions are widely used in genomics, cancer research, and precision medicine. The advanced sequencing systems of the company deliver high accuracy results while maintaining fast performance and extensive capacity, which makes them essential tools for contemporary genetic research. The company develops innovative solutions for next-generation sequencing systems, which drive the expansion of the SNP market while producing comprehensive understanding of genetic variations and their connections to disease development.

 

• QIAGEN N.V.

Headquarters: Hilden, Germany

QIAGEN N.V. operates as a leading company in the SNP market through its extensive portfolio of sample preparation and molecular testing and genomic analysis products. The company establishes solutions that enable researchers and clinicians to perform genetic variation analysis with high efficiency. Its products for SNP genotyping operate in multiple fields including disease research and diagnostics and personalized medicine. QIAGEN delivers high-quality reagents and kits and bioinformatics tools which scientists use to obtain accurate results. The company develops molecular diagnostics and genomic research solutions which combine advanced technologies with user-friendly platforms for worldwide application.

 

• F. Hoffmann-La Roche Ltd

Headquarters: Basel, Switzerland

F. Hoffmann-La Roche Ltd operates as a global healthcare company which participates in the SNP market through its diagnostic and pharmaceutical business units. The company creates advanced genomic testing solutions which allow SNP analysis for disease diagnosis and personalized medicine. Roche technologies find extensive application in oncology and genetic testing and clinical research. The company enables precise genetic variation detection through its commitment to developing innovative healthcare solutions which work as one integrated system. Roche maintains a strong international presence while investing in research and development to advance genomic diagnostics which enhance patient outcomes in all parts of the world.

 

• Agilent Technologies

Headquarters: Santa Clara, California, USA

Agilent Technologies is a key contributor to the SNP market, offering advanced analytical instruments and genomic solutions. The company provides microarray platforms, reagents, and software tools for SNP genotyping and genetic analysis. Research laboratories and biotechnology companies and clinical settings use its technologies. Agilent supports genetic variation research through its accurate dependable high-throughput solutions. The company uses continuous innovation together with its research focus to develop new genomics and precision medicine technologies. The global operations of Agilent help the company to advance its business while developing new innovations in the SNP market.

 

Are you ready to discover more about the single nucleotide polymorphism (snp) market?

The report provides an in-depth analysis of the leading companies operating in the global single nucleotide polymorphism (snp) market. It includes a comparative assessment based on their product portfolios, business overviews, geographical footprint, strategic initiatives, market segment share, and SWOT analysis. Each company is profiled using a standardized format that includes:

 

Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Single Nucleotide Polymorphism (SNP) Market.

 

Company Profiles

1. Thermo Fisher Scientific

• Business Overview
• Company Snapshot
• Products Overview
• Company Market Share Analysis
• Company Coverage Portfolio
• Financial Analysis
• Recent Developments
• Merger and Acquisitions
• SWOT Analysis

1. Illumina, Inc.
2. QIAGEN N.V.
3. F. Hoffmann-La Roche Ltd
4. Agilent Technologies
5. Bio-Rad Laboratories
6. LGC Group
7. Standard BioTools Inc.
8. Revvity, Inc.
9. Others.

 

Conclusion

The global Single Nucleotide Polymorphism (SNP) market is witnessing steady growth, driven by rising demand for decentralized renewable energy, technological advancements, and supportive government policies. Single Nucleotide Polymorphism (SNP) provide cost-effective, sustainable solutions for residential, commercial, and off-grid applications, enabling energy independence and reducing carbon emissions. Innovations in turbine efficiency, hybrid systems, and smart monitoring further enhance performance and reliability. Leading companies such as Bergey Windpower, Northern Power Systems, Xzeres Wind, Eocycle Technologies, and Kingspan Group are expanding their global presence, contributing to market development. Overall, Single Nucleotide Polymorphism (SNP) play a vital role in advancing clean energy adoption worldwide.

 

Our Reports:

https://www.sphericalinsights.com/reports/europe-lpg-market

https://www.sphericalinsights.com/reports/germany-carbon-nanotubes-market

https://www.sphericalinsights.com/reports/germany-smart-clothing-market

https://www.sphericalinsights.com/reports/pediatric-non-invasive-wearables-market

https://www.sphericalinsights.com/reports/india-battery-energy-storage-systems-market

https://www.sphericalinsights.com/reports/india-cervical-cancer-diagnostic-market

https://www.sphericalinsights.com/reports/india-ferrosilicon-market

 

About the Spherical Insights & Consulting

Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.

Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements. 

 

CONTACT US:

For More Information on Your Target Market, Please Contact Us Below:    

Phone: +1 303 800 4326 (the U.S.)

Phone: +91 90289 24100 (APAC)

Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com

Contact Us: https://www.sphericalinsights.com/contact-us

Follow Us: LinkedIn | Facebook | Twitter